Cencora FKA Amerisourcebergen Corporation
Pharmaceutical Services
Based in PA
AI Overview
With $1.4M in lobbying spend across 28 quarterly filings, Cencora FKA Amerisourcebergen Corporation is a significant lobbying presence. Their lobbying covers 1 issue area. Active from 2018 to 2025.
Spending Trend
View as table
| Year | Lobbying Spend |
|---|---|
| 2018 | $150K |
| 2019 | $200K |
| 2020 | $200K |
| 2021 | $150K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $150K |
| 2025 | $150K |
Issues Lobbied
Lobbying Firms
Lobbyists
What They Lobby About
These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Health Issues
Prompt Pay, ASP, Medicare Part B Issues, Medicare Access and CHIP Re authorization Act (MACRA)implementation, Drug Quality and Security Act Implementation, Direct fees
Prompt Pay, ASP, Medicare Part B Issues, Medicare Access and CHIP Re authorization Act (MACRA)implementation, Drug Quality and Security Act Implementation, Direct and indirect remuneration - drug pricing
Prompt Pay; ASP; Medicare Part B Issues; Medicare Access and CHIP Re authorization Act (MACRA)implementation; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration - Drug Pricing
Prompt Pay; ASP; Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration - Drug Pricing
Prompt Pay; ASP; Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration - Drug Pricing; Coronavirus and drug shortage issues.
Prompt Pay; Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration-Drug Pricing; Coronavirus and drug shortage issues.
Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration-Drug Pricing; Coronavirus and drug shortage issues.
Medicare Part B Issues; Drug Quality and Security Act Implementation; Direct and Indirect Remuneration-Drug Pricing; Coronavirus and drug shortage issues; Build Back Better legislation
Showing 8 of 13 unique descriptions from filings.
Related Analysis
Related Investigations
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.